The objectives of the workshop are:

- To hear the views of stakeholders and experts:
  - on the draft RWE reflection paper open for public consultation in May
  - on priorities for further regulatory guidance development and collaboration beyond the reflection paper.
- To engage with stakeholders on novel RWE methods in regulatory decision making.

Target Audience:

- Internal: EMA staff and European Medicines Regulatory Network (EMRN)
- External: Representatives from pharmaceutical industry, academia, regulatory bodies, health technology assessment (HTA), patients and healthcare professionals (HCP) by providing insights on use of RWE for regulatory decision making.

Format:

- One day hybrid workshop (online and in person by invitation)
Friday, 14 June 2024, 09:00 – 16:30 CEST

Chaired by Peter Arlett (EMA, Head of Data Analytics and Methods Task Force (TDA), BDSG Co-chair) and Jeppe Larsen (Danish Medicines Agency, BDSG Co-chair)

08:45  Joining and technical checks (for online)

09:00  Welcome

Opening remarks from EMA
Emer Cooke (EMA Executive Director) – 5 min

Opening remarks from BDSG
Jeppe Larsen (HMA BDSG Co-chair) – 5 min

Scene-setting and goals of the workshop
Patrice Verpillet (EMA, Head of RWE) – 10 min

EU-funded initiatives in the use of new RWE methods
Tomasz Dyla (DG Research and Innovation) – 10 min

09:30-10:50  Session 1: Presentation and discussion of RWE Reflection paper

Chairied by Kit Roes (MWP Chair) and Mencía de Lemus Belmonte (Patient representative)

Presentation of the RWE Reflection paper - 40 min
Xavier Kurz (ESEC RWE)

Panel discussion with invited stakeholders from pharmaceutical industry (Almath Spooner), academia (Helga Gardarsdottir), patients (Bettina Ryll) and HCP (Holger Schunemann) - 40 min
Moderator: Olaf Klungel

10:50-11:15  Coffee Break

11:15-12:45  Session 2a: RWE methods to support EU regulatory decision making

Chairied by Harald Enzmann (CHMP Chair) and Daniel Morales (EMA)

Target Trial Emulation and Estimand frameworks for Non-interventional Studies with causal objectives

Introduction – 15 min
Xabier Garcia de Albeniz (RTI Barcelona)

Presentations of Target Trial Emulation in a regulatory context – 45 min
- Use of Estimands in Target Trial Emulation (Juan Jose Abellan - EMA)
- DARWIN CC use case (Daniel Prieto Alhambra)
- Industry use case (Rima Izem - Novartis)
Panel discussion with panellists from pharmaceutical industry (Helene Nordal), academia (Anthony Matthews), regulatory bodies (Rhea Fitzgerald) – 30 min

12:45-13:30 Lunch

13:30-15:00 Session 2b: RWE methods to support EU regulatory decision making

Chaired by Carla Torre (CHMP) and Marcia Rueckbeil (EMA)

RWD-derived External Controls in Clinical Trials

Introduction – 15 min
Elina Asikanius (SAWP, MWP)

Presentations of RWD as external control in a regulatory context – 45 min
  ▪ Industry use case (Maurille Feudjo Tepie - UCB)
  ▪ FDA use case - Donna Rivera (FDA)
  ▪ EMA use case (Abecma) – joint presentation by Andrea Buzzi (EMA) + Theodor Framke (Methodology ESEC)

Panel discussion with panellists from pharmaceutical industry (Mehmet Burcu), academia (Denis Lacombe), HCP (Jan Cornelissen), regulatory body (Bruno Delafont), – 30 min

15:00-15:20 Coffee Break

15:20-16:20 Session 3: The next three years: Roadmap for RWE guidance

Chaired by Jeppe Larsen (BDSG Co-chair) and Kit Roes (MWP Chair)

Introduction to Methodology Working Party – 15 min
Kit Roes (MWP Chair)

MWP Roadmap for the development of RWE guidance – 15 min
Olaf Klungel (MWP Member)

Panel discussion with invited stakeholders from pharmaceutical industry (Marieke Schoonen), academia (Viviana Giannuzzi), patients (George Paliouras) and HCP (Ioana Agache) – 30 min

16:20-16:30 Summary of the workshop and conclusion

Concluding remarks
Peter Arlett (EMA BDSG Co-chair)